Stroke therapy using menstrual blood stem-like cells: Method

Maria Carolina Oliveira Rodrigues, Svitlana Garbuzova-Davis, Paul R. Sanberg, Júlio C. Voltarelli, Julie G. Allickson, Nicole Kuzmin-Nichols, Cesario V. Borlongan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cerebrovascular diseases are the third leading cause of death and the primary cause of longterm disability in the United States. Most patients, excluded from the available treatment with plasminogen activator (tPA), present permanent neurological impairment and may benefit from restorative treatments with stem cells. Inflammation is a key feature in stroke and it plays a dual role, either increasing injury in early phases or impairing neural survival at later stages. Stem cells can be opportunely used to modulate inflammation, abrogate cell death and, therefore, preserve neural function. To date, there is no consensus about the most adequate cell type, route of delivery or timing for transplantation, as experimental and clinical studies are still inconclusive. Menstrual blood stem cells have been recently studied for their availability, proliferative capacity, pluripotentiality and angiogenic features, which make them a relevant resource for the treatment of stroke.

Original languageEnglish (US)
Title of host publicationStem Cells and Cancer Stem Cells, Volume 2
Subtitle of host publicationStem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury: Volume 2
PublisherSpringer Netherlands
Pages191-197
Number of pages7
ISBN (Electronic)9789400720169
ISBN (Print)9789400720152
DOIs
StatePublished - Jan 1 2012

Fingerprint

Dive into the research topics of 'Stroke therapy using menstrual blood stem-like cells: Method'. Together they form a unique fingerprint.

Cite this